Free Trial

Cartesian Therapeutics (RNAC) Stock Forecast & Price Target

$16.69
-1.73 (-9.39%)
(As of 07/18/2024 ET)

Cartesian Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 7 Wall Street analysts who have issued ratings for Cartesian Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for RNAC.

Consensus Price Target

$43.83
162.63% Upside
High Forecast$50.00
Average Forecast$43.83
Low Forecast$39.00

According to the 7 analysts' twelve-month price targets for Cartesian Therapeutics, the average price target is $43.83. The highest price target for RNAC is $50.00, while the lowest price target for RNAC is $39.00. The average price target represents a forecasted upside of 162.63% from the current price of $16.69.

TypeCurrent Forecast
7/19/23 to 7/18/24
1 Month Ago
6/19/23 to 6/18/24
3 Months Ago
4/20/23 to 4/19/24
1 Year Ago
7/19/22 to 7/19/23
Consensus Rating
Moderate Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
6 Buy rating(s)
6 Buy rating(s)
2 Buy rating(s)
N/A
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$43.83$45.00$51.00N/A
Forecasted Upside162.63% Upside84.74% Upside221.56% UpsideN/A
Get Cartesian Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.

RNAC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RNAC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cartesian Therapeutics Stock vs. The Competition

TypeCartesian TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside161.38% Upside1,354.25% Upside8.78% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/8/2024Needham & Company LLC
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00+147.50%
7/3/2024HC Wainwright
3 of 5 stars
M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$54.00 ➝ $49.00+178.09%
7/3/2024Canaccord Genuity Group
1 of 5 stars
 Boost TargetBuy ➝ Buy$38.00 ➝ $43.00+140.90%
7/2/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/24/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+57.11%
4/23/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/23/2024SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$39.00+113.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:20 PM ET.

RNAC Forecast - Frequently Asked Questions

What is Cartesian Therapeutics' forecast for 2024?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Cartesian Therapeutics is $43.83, with a high forecast of $50.00 and a low forecast of $39.00.

Should I buy or sell Cartesian Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cartesian Therapeutics in the last year. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RNAC shares.

Does Cartesian Therapeutics's stock price have much upside?

According to analysts, Cartesian Therapeutics's stock has a predicted upside of 122.40% based on their 12-month stock forecasts.

Has Cartesian Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, Cartesian Therapeutics's stock had 1 downgrade by analysts.

What analysts cover Cartesian Therapeutics?

Cartesian Therapeutics has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, Leerink Partnrs, Mizuho, Needham & Company LLC, Oppenheimer, and SVB Leerink in the past 90 days.

Do Wall Street analysts like Cartesian Therapeutics more than its competitors?

Analysts like Cartesian Therapeutics more than other "medical" companies. The consensus rating score for Cartesian Therapeutics is 2.86 while the average consensus rating score for "medical" companies is 2.71. Learn more on how RNAC compares to other companies.


This page (NASDAQ:RNAC) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners